Pseudomyxoma peritonei can involve multiple areas of the abdominal cavity, making detailed assessment of disease distribution important when considering an appropriate treatment pathway.
For patients exploring pseudomyxoma treatment, the first consideration is often the extent and location of disease within the peritoneal cavity. Imaging, pathology and clinical assessment can help determine whether the disease may be amenable to surgery or other specialised approaches.
In selected patients, cytoreductive surgery may be considered to remove visible tumour deposits. Depending on the individual disease pattern, HIPEC may also form part of the treatment strategy. The suitability of these approaches depends on factors such as disease burden, involvement of abdominal structures, previous treatment and the patient's overall health.
Dr. Ninad V. Katdare's work in peritoneal surface malignancies includes complex surgical planning where the distribution of disease is an important consideration.
Modern cancer care may involve a combination of surgical and systemic treatments. Depending on tumour characteristics and treatment objectives, chemotherapy, targeted therapy and immunotherapy may also have a role in the broader treatment plan.
Pseudomyxoma peritonei does not follow a single treatment pathway for every patient. The distribution of peritoneal disease, the possibility of achieving appropriate tumour reduction and the patient's previous treatment history are important considerations when evaluating available options.
For patients seeking a clearer understanding of specialised pseudomyxoma and peritoneal cancer treatment options in Vile Parle, Dr Ninad Katdare Cancer Surgeon can explain how disease extent and individual clinical factors may influence treatment planning.
